MX2017004418A - Composicion farmaceutica de derivado de aminodihidrotiazina condensado. - Google Patents

Composicion farmaceutica de derivado de aminodihidrotiazina condensado.

Info

Publication number
MX2017004418A
MX2017004418A MX2017004418A MX2017004418A MX2017004418A MX 2017004418 A MX2017004418 A MX 2017004418A MX 2017004418 A MX2017004418 A MX 2017004418A MX 2017004418 A MX2017004418 A MX 2017004418A MX 2017004418 A MX2017004418 A MX 2017004418A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
fused aminodihydrothiazine
aminodihydrothiazine derivative
derivative
fused
Prior art date
Application number
MX2017004418A
Other languages
English (en)
Other versions
MX370338B (es
Inventor
Zaima Yasuhiro
Kazama Kazuo
Arase Shuntaro
NAGANE Kentaro
Horie Kanta
Ueki Yosuke
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2017004418A publication Critical patent/MX2017004418A/es
Publication of MX370338B publication Critical patent/MX370338B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona una composición farmacéutica que comprende un compuesto representado por la fórmula (1): (ver Fórmula) o N-[3-((4aS,5R,7aS)-2-amino-5-metil-4a,5,7,7a-tetrahidro -4H-furo[3,4-d] [1,3]tiazin-7a-il)-4-fluorofenil)-5-difluorometilp irazin-2-carboxamida, o una sal farmacéuticamente aceptable del anterior, y una sal de un compuesto que tiene un grupo hidrocarbonado alifático saturado C12-22.
MX2017004418A 2014-10-10 2015-10-08 Composicion farmaceutica de derivado de aminodihidrotiazina condensado. MX370338B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014209289 2014-10-10
PCT/JP2015/078688 WO2016056638A1 (ja) 2014-10-10 2015-10-08 縮合アミノジヒドロチアジン誘導体の医薬組成物

Publications (2)

Publication Number Publication Date
MX2017004418A true MX2017004418A (es) 2017-06-26
MX370338B MX370338B (es) 2019-12-10

Family

ID=55653242

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004418A MX370338B (es) 2014-10-10 2015-10-08 Composicion farmaceutica de derivado de aminodihidrotiazina condensado.

Country Status (14)

Country Link
US (1) US10117876B2 (es)
EP (1) EP3205343B1 (es)
JP (3) JP6590822B2 (es)
KR (1) KR102524217B1 (es)
CN (1) CN107106568B (es)
AU (1) AU2015329027B2 (es)
BR (1) BR112017007293B1 (es)
CA (1) CA2963761C (es)
ES (1) ES2909797T3 (es)
IL (1) IL251559B (es)
MX (1) MX370338B (es)
RU (1) RU2710227C2 (es)
SG (1) SG11201702632QA (es)
WO (1) WO2016056638A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10117876B2 (en) * 2014-10-10 2018-11-06 Eisai R&D Management Co., Ltd. Pharmaceutical composition of fused aminodihydrothiazine derivative
BR112019008359A2 (pt) * 2016-10-27 2019-10-01 Eisai R&D Man Co Ltd método para tratamento da doença de alzheimer, e, composição farmacêutica.
JP6326114B2 (ja) * 2016-11-01 2018-05-16 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1070496A4 (en) * 1998-04-08 2004-07-21 Kyowa Hakko Kogyo Kk METHOD FOR PRODUCING TABLETS AND TABLET
ATE451925T1 (de) * 2004-10-06 2010-01-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung, verfahren zu ihrer herstellung und verfahren zur stabilisierung einer dihydropyridin-verbindung in einer medizinischen zusammensetzung
JP5158922B2 (ja) * 2006-02-24 2013-03-06 塩野義製薬株式会社 ビタミンｂ１２類含有組成物
US8158620B2 (en) * 2008-01-18 2012-04-17 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivatives
WO2009101940A1 (ja) * 2008-02-11 2009-08-20 Dainippon Sumitomo Pharma Co., Ltd. 溶出性の改善された錠剤
BR112013016241A2 (pt) * 2011-01-21 2016-07-12 Eisai R&D Man Co Ltd composto, e, método para fabricar um composto
JP2014037356A (ja) * 2012-08-13 2014-02-27 Takada Seiyaku Kk カンデサルタンシレキセチル経口製剤
US20140271911A1 (en) * 2014-03-26 2014-09-18 James Wallace Lithium and a beta-secretase inhibitor for the treatment of alzheimer's disease
US10117876B2 (en) * 2014-10-10 2018-11-06 Eisai R&D Management Co., Ltd. Pharmaceutical composition of fused aminodihydrothiazine derivative

Also Published As

Publication number Publication date
EP3205343A1 (en) 2017-08-16
RU2017111801A (ru) 2018-11-13
CN107106568A (zh) 2017-08-29
ES2909797T3 (es) 2022-05-10
BR112017007293B1 (pt) 2022-12-13
US20180263998A1 (en) 2018-09-20
EP3205343A4 (en) 2018-06-06
IL251559B (en) 2021-02-28
RU2710227C2 (ru) 2019-12-25
IL251559A0 (en) 2017-05-29
JP2020125330A (ja) 2020-08-20
MX370338B (es) 2019-12-10
KR102524217B1 (ko) 2023-04-21
KR20170066397A (ko) 2017-06-14
JP2019196395A (ja) 2019-11-14
CA2963761C (en) 2023-10-17
AU2015329027B2 (en) 2020-04-30
CA2963761A1 (en) 2016-04-14
AU2015329027A1 (en) 2017-04-27
BR112017007293A2 (pt) 2017-12-26
US10117876B2 (en) 2018-11-06
WO2016056638A1 (ja) 2016-04-14
RU2017111801A3 (es) 2019-02-12
SG11201702632QA (en) 2017-05-30
EP3205343B1 (en) 2022-01-26
JPWO2016056638A1 (ja) 2017-07-20
JP6590822B2 (ja) 2019-10-16
CN107106568B (zh) 2023-09-26

Similar Documents

Publication Publication Date Title
MX2021002978A (es) Lactamas biciclicas y metodos de uso de las mismas.
EA201791692A1 (ru) 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
WO2016011390A8 (en) Irak4 inhibiting agents
PH12018500061A1 (en) Oxysterols and methods of use thereof
WO2016079751A3 (en) A process for preparation of vortioxetine and polymorphs thereof
MX2015011913A (es) Moduladores de acido oxabiciclo[2.2.2] gpr120.
MA39956A (fr) Analogues du benzomorphane et leur utilisation
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
MY182884A (en) Pyrazole-amide compound and medicinal uses therefor
MX2019003724A (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
PH12016501517B1 (en) Tetrazolone-substituted dihydropyridinone mgat2 inhibitors
MX2015011932A (es) Moduladores de gpr120 de acido biciclo[2.2.2].
MX2015015562A (es) Dihidropiridinona como inhibidores de monoacilglicerol aciltransferasa 2.
MX2016015247A (es) Derivados de benceno-sulfonamida y su uso como moduladores del receptor c huerfano relacionado a acido retinoico (rorc).
PH12018500903A1 (en) Pyranodipyridine compound
PH12016502246B1 (en) Carboxamide derivatives
EA201692298A1 (ru) Производные карбоксамидов
MX362919B (es) Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1].
WO2018039077A8 (en) Therapeutic compounds
MX2017004418A (es) Composicion farmaceutica de derivado de aminodihidrotiazina condensado.
WO2015191681A3 (en) Substituted pyridinones as mgat2 inhibitors
EA201691741A1 (ru) Фармацевтическая композиция
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
MY176508A (en) Anti-enterovirus 71 thiadiazolidine derivative

Legal Events

Date Code Title Description
FG Grant or registration